Laura Lovett
A new study in The Lancet found that a deep-learning algorithm was able to detect vision-threatening retinopathy with 94.7% accuracy.
The feature is geared toward offering clinicians a holistic view of the patient.
The pair will research how aging and the environment impact skin, and develop new digital diagnostic tools for dermatology.
The company is looking to use the new funds to expand internationally.
One Medical shareholders will now own 73% of the joint company and Iora Health shareholders will have 27%.
The Boston and Tel Aviv-based company includes a predictive analytics tool which helps intervene in a person's aging trajectory.
OMERS Growth Equity and Kaiser Permanente Group Trust led the round, with participation from McKesson Ventures and B Capital Group.
Grand Rounds' CEO Owen Tripp will continue on as the CEO of the combined entity.
The health tech company teamed up with New York State's Department of Public Health to distribute the vaccines.
The company plans to continue to focus on the metabolic health space.